# Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission

> **NCT00761579** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 190 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone

## Key facts

- **NCT ID:** NCT00761579
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-10
- **Final completion:** 2010-12
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2014-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761579, "Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00761579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*